TY - JOUR
T1 - Single gold nanoplasmonic sensor for clinical cancer diagnosis based on specific interaction between nucleic acids and protein
AU - Ma, Xingyi
AU - Truong, Phuoc Long
AU - Anh, Nguyen Hung
AU - Sim, Sang Jun
N1 - Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government ( Ministry of Science, ICT & Future Planning ) (Grant no. NRF-2013R1A2A1A01015644/2010-0027955 ), and the Korea CCS R&D Center grant funded by the Korea government ( Ministry of Science, ICT & Future Planning ) (Grant no. 2011-0031997 ) of the Republic of Korea.
Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/5/5
Y1 - 2015/5/5
N2 - Plasmonic nanomaterials reveal noble optical properties for next-generation biosensors. Nanoplasmonic biosensors have become simple, sensitive, smart, and consistent with advanced healthcare programs requirements. Notably, an individual nanoparticle analysis can yield unique target information, based on which the next-generation biosensor is revolutionary for end-point detection (single or multiplex), and can be functionally extended to biological phenomena monitoring. Here, we present a single nanoplasmonic sensing technology based on localized surface plasmon resonance for label-free and real-time detection of highly reliable cancer markers (mutant gene and telomerase) in clinical samples. The sensor specifically detects mutant DNA, and can detect telomerase from as few as 10 HeLa cells. This approach can be easily translated to detect other pathological targets with high sensitivity and specificity, and monitor key interactions between biomolecules such as nucleic acids and proteins during disease development in real time. This system has great potential to be further developed for on-chip and simultaneous analysis of multiple targets and interactions.
AB - Plasmonic nanomaterials reveal noble optical properties for next-generation biosensors. Nanoplasmonic biosensors have become simple, sensitive, smart, and consistent with advanced healthcare programs requirements. Notably, an individual nanoparticle analysis can yield unique target information, based on which the next-generation biosensor is revolutionary for end-point detection (single or multiplex), and can be functionally extended to biological phenomena monitoring. Here, we present a single nanoplasmonic sensing technology based on localized surface plasmon resonance for label-free and real-time detection of highly reliable cancer markers (mutant gene and telomerase) in clinical samples. The sensor specifically detects mutant DNA, and can detect telomerase from as few as 10 HeLa cells. This approach can be easily translated to detect other pathological targets with high sensitivity and specificity, and monitor key interactions between biomolecules such as nucleic acids and proteins during disease development in real time. This system has great potential to be further developed for on-chip and simultaneous analysis of multiple targets and interactions.
KW - Cancer cell
KW - DNA mutation
KW - Gold nanoparticle (AuNP)
KW - Localized surface plasmon resonance (LSPR)
KW - Nanoplasmonic sensor
KW - Telomerase activity
UR - http://www.scopus.com/inward/record.url?scp=84922275717&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2014.06.038
DO - 10.1016/j.bios.2014.06.038
M3 - Article
C2 - 24996253
AN - SCOPUS:84922275717
SN - 0956-5663
VL - 67
SP - 59
EP - 65
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
ER -